Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters (Q35795269)

10 August 2017

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters (English)

1 reference

10 August 2017

7

Nicolas von Ahsen

0 references

Edelgard Lindhoff-Last

8

object named as

Edelgard Lindhoff-Last

0 references

author name string

Christof Geisen

1

1 reference

10 August 2017

Beate Luxembourg

2

1 reference

10 August 2017

Matthias Watzka

3

1 reference

10 August 2017

Stefan W Toennes

4

1 reference

10 August 2017

Katja Sittinger

5

1 reference

10 August 2017

Milka Marinova

6

1 reference

10 August 2017

Nicolas von Ahsen

7

1 reference

10 August 2017

Edelgard Lindhoff-Last

8

1 reference

10 August 2017

Erhard Seifried

9

1 reference

10 August 2017

Johannes Oldenburg

10

1 reference

10 August 2017

language of work or name

1 reference

26 November 2010

1 reference

European Journal of Clinical Pharmacology

10 August 2017

1 reference

10 August 2017

67

1 reference

10 August 2017

4

1 reference

10 August 2017

371-381

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-010-0950-y

10 August 2017

0 references

cites work

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Pharmacogenetics of oral anticoagulants: a basis for dose individualization

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

CYP4F2 genetic variant alters required warfarin dose

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Biochemical markers of alcoholism.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Association of warfarin dose with genes involved in its action and metabolism

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Drug metabolism and variability among patients in drug response

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

The influence of age on the response to anticoagulants

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement

12 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0950-Y

CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0950-Y

The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0950-Y

Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0950-Y

Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0950-Y

Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0950-Y

Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0950-Y

Genetic determinants of warfarin dosing in the Han-Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0950-Y

Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0950-Y

VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0950-Y

Determination of bleeding risk using genetic markers in patients taking phenprocoumon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0950-Y

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0950-Y

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0950-Y

A genome-wide association study of acenocoumarol maintenance dosage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0950-Y

Phosphatidylethanol as a sensitive and specific biomarker: comparison with gamma-glutamyl transpeptidase, mean corpuscular volume and carbohydrate-deficient transferrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0950-Y

Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

VKORCI haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3291838

Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin

15 November 2018

1 reference

12 December 2020

Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon

1 reference

12 December 2020

Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy

1 reference

12 December 2020

Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy

1 reference

12 December 2020

10.1007/S00228-010-0950-Y

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

1 reference